Patent ID: 11866518
Assignee: BICYCLETX LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 2:
3. The peptide ligand as defined in claim 1, wherein said peptide ligand comprises an amino acid sequence selected from:
A-(SEQ ID NO: 119)-A (hereinafter referred to as Example 161);
A-(SEQ ID NO: 120)-A (hereinafter referred to as Example 162);
A-(SEQ ID NO: 121)-A (hereinafter referred to as Example 163);
(SEQ ID NO: 121) (hereinafter referred to as Example 185);
A-(SEQ ID NO: 122)-A (hereinafter referred to as Example 164);
YATTQV-(SEQ ID NO: 122)-A (hereinafter referred to as Example 171);
KDNRVD-(SEQ ID NO: 122)-A (hereinafter referred to as Example 172);
EYQRDV-(SEQ ID NO: 122)-A (hereinafter referred to as Example 173);
A-(SEQ ID NO: 122)-SNSYDMA (hereinafter referred to as Example 174);
A-(SEQ ID NO: 122)-SESVHTA (hereinafter referred to as Example 175);
A-(SEQ ID NO: 122)-SSDTHDA (hereinafter referred to as Example 176);
A-(SEQ ID NO: 122)-KPDHVDA (hereinafter referred to as Example 177);
A-(SEQ ID NO: 122)-ANY (hereinafter referred to as Example 186);
RVNTHQ-(SEQ ID NO: 122)-A (hereinafter referred to as Example 190);
YDRDFT-(SEQ ID NO: 122)-A (hereinafter referred to as Example 191);
EVDTYP-(SEQ ID NO: 122)-A (hereinafter referred to as Example 192);
A-(SEQ ID NO: 122)-ADGLYDA (hereinafter referred to as Example 193);
AHP-(SEQ ID NO: 123)-A (hereinafter referred to as Example 165);
YGA-(SEQ ID NO: 124)-A (hereinafter referred to as Example 166);
A-(SEQ ID NO: 125)-APN (hereinafter referred to as Example 167);
A-(SEQ ID NO: 126)-YDE (hereinafter referred to as Example 168);
A-(SEQ ID NO: 127)-AGD (hereinafter referred to as Example 169);
A-(SEQ ID NO: 128)-AHP (hereinafter referred to as Example 170);
(SEQ ID NO: 129) (hereinafter referred to as Example 178);
(SEQ ID NO: 130) (hereinafter referred to as Example 179);
(SEQ ID NO: 131) (hereinafter referred to as Example 180);
(SEQ ID NO: 132) (hereinafter referred to as Example 181);
(SEQ ID NO: 133) (hereinafter referred to as Example 182);
A-(SEQ ID NO: 134)-A (hereinafter referred to as Example 183);
A-(SEQ ID NO: 135)-A (hereinafter referred to as Example 184);
RAP-(SEQ ID NO: 136)-A (hereinafter referred to as Example 187);
SHV-(SEQ ID NO: 137)-A (hereinafter referred to as Example 188);
RDL-(SEQ ID NO: 138)-A (hereinafter referred to as Example 189);
(SEQ ID NO: 139) (hereinafter referred to as Example 194); and
(SEQ ID NO: 140) (hereinafter referred to as Example 195);
or a pharmaceutically acceptable salt thereof.